A Phase 3 study of an experimental gene therapy for choroideremia failed to meet its primary endpoint, and also did not show efficacy on key secondary endpoints, Biogen Inc announced on 14 June. Choroideremia is a rare, inherited retinal disease resulting in progressive vision loss, ultimately leading to blindness.
